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Abstract 
 
Background: Because of low incidence, mixed study populations and paucity of clinical and 
histological data, the management of adult brainstem gliomas remains non-standardized. We 
here describe characteristics, treatment and outcome of patients with exclusively 
histologically confirmed adult brainstem gliomas. 
Methods: A retrospective chart review of adults (> age 18 years) was conducted. Brainstem 
glioma was defined as a glial tumor located in the midbrain, pons or medulla. Characteristics, 
management and outcome were analyzed. 
Results: 21 patients (17 males; median age 41 years) were diagnosed between 2004 and 
2012 by biopsy (n=15), partial (n=4) or complete resection (n=2). Diagnoses were 
glioblastoma (WHO grade IV, n=6), anaplastic astrocytoma (WHO grade III, n=7), diffuse 
astrocytoma (WHO grade II, n=6) and pilocytic astrocytoma (WHO grade I, n=2). Diffuse 
gliomas were mainly located in the pons and frequently showed MRI contrast enhancement. 
Endophytic growth was common (16 versus 5). Postoperative therapy in low-grade (WHO 
grade I/II) and high-grade gliomas (WHO grade III/IV) consisted of radiotherapy alone (3 in 
each group), radiochemotherapy (2 versus 6), chemotherapy alone (0 versus 2) or no 
postoperative therapy (3 versus 1). Median PFS (24.1 versus 5.8 months; log-rank, p=0.009) 
and mOS (30.5 versus 11.5 months; log-rank, p=0.028) was significantly better in WHO 
grade II than in WHO grade III/IV tumors. Second-line therapy considerably varied.  
Conclusions: Histologically verification of adult brainstem glioma is feasible and has an 
impact on postoperative treatment. Low-grade gliomas can simple be followed or treated with 
radiotherapy alone. Radiochemotherapy with temozolomide can safely be prescribed for 
high-grade gliomas without additional CNS toxicities. 
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Introduction 
Brainstem gliomas (BSGs) are devastating malignancies of the central nervous system 
(CNS) and comprise 1-2% of adult primary brain tumors [1; 2]. The median overall survival 
(mOS) is reported to be five years in diffuse intrinsic low-grade BSGs (LG-BSG) [1]. High-
grade BSGs (HG-BSGs) are associated with greater morbidity and mortality with a median 
overall survival ranging from 11 to 17 months [3-5]. In three out of four patients the tumor is 
localized in the pontine region, both in adults and in children [2; 5]. The midbrain and the 
cervico-medullary region are less commonly affected. Based on magnetic resonance imaging 
(MRI) four phenotypes can be defined: (1) non-enhancing, diffuse intrinsic glioma, (2) 
localized enhancing lesions, (3) focal tectal gliomas, and (4) other patterns [3]. Stereotactic 
brainstem biopsy should be the diagnostic standard of care in adults with enhancing lesions 
as it has the greatest impact on therapeutic decisions [1; 6]. With stereotactic biopsy a 
definitive diagnosis can be obtained in over 95% of the patients [7]. Despite reluctance of 
clinicians for biopsy and exclusive radiological diagnosis for recent years [5], the 
complication rate of stereotactic biopsy in experienced hands is low. Persistent disability and 
mortality has been reported at 1.7% and 0.9%, respectively [7]. On multivariate analysis 
short duration of symptoms, necrosis on MRI and higher histological grade were independent 
negative prognostic factors [3]. Kesari and colleagues identified non-caucasian ethnicity, 
higher age, higher tumor grade and pontine tumor location as poor prognostic factors for 
survival [4]. A short time between symptom onset and diagnosis was also associated with a 
worse outcome of diffuse brainstem gliomas [5; 8].  
Depending on severity of symptoms and tumor grade, radiotherapy has historically been the 
treatment of choice [2; 8]. However, irradiation doses vary among the reported series [3; 4; 8-
10]. A few recent reports have administered concomitant radiochemotherapy with 
temozolomide [8; 9], however prospective protocols in a pediatric population were 
disappointing [11-14]. No agreement in the management of recurrent or progressive 
brainstem glioma exists.  
Most recent reports were not only retrospective studies, but often analyzed a mixed patient 
population of both adults and children [2; 10] and contained a substantial proportion of 
patients without histological verification of the presumed diagnosis [3; 4; 8]. Only one recent 
case series with histologically verified tumors in patients older than 60 years was published 
[9]. Hence, due to the paucity of data, clinical decisions for individual patients remain 
challenging, and an established treatment other than radiotherapy does not exist. In this 
study we describe the diagnosis, clinical management and outcome in a cohort of adult 
patients with histologically verified LG- and HG-BSG. 
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Patients and methods 
We performed a retrospective review of records of adult patients (>18 years) treated for BSG 
at four neuro-oncology centers in Switzerland between 2004 and 2012. This study was 
approved by the institutional ethic committee. BSGs were defined as tumors with the main 
mass in the midbrain, pons or medulla [3]. Gliomas with extension to the cerebellum, the 
thalamus and the spinal cord were also included. Histological confirmation of the diagnosis of 
BSG was required to include patients in this study.  BSGs of any grade were accepted. 
Ependymomas as a distinct clinical and molecular entity were excluded. 
Clinical data comprised age at diagnosis, gender, time from first imaging to histological 
diagnosis, presenting signs and symptoms, location, treatment complications and 
neurological deterioration after surgery, written reports of cerebral MRI images (T1- and T2-
weight images in two planes before and after gadolinium) and written pathological reports. 
Results of molecular analyses were also collected. Data of first-line and follow-up therapy 
including degree of surgery (biopsy, resection), dose and timing of radiotherapy and 
chemotherapy were included. Outcome was calculated for median progression free survival 
(mPFS) and overall survival (mOS) based on the Kaplan-Meier estimates [15]. Survival 
curves were compared with the log-rank test (Mantel-Cox). PFS and OS of first-line therapy 
were defined from initial histological diagnosis to clinical and/or radiological progression or 
death.  
 
Results 
Characteristics 
Twenty-one adult patients were identified (17 males) from local data basis of the participating 
centers. Median age at surgery was 41 years (range, 20-81). Patients with HG-BSGs were 
older than those with LG-BSGs (median, 48 versus 34 years, t-test; p=0.56). The median 
time from initial imaging to surgery was approximately 2 months in both groups. The main 
clinical symptoms at presentation were ataxia, oculomotor symptoms, dizziness and a 
sensory and/or motor hemisyndrome (Table 1). Most BSGs were located in the pons (n=8). 
Additionally, seven BSGs extended from the pons to the midbrain or medulla (Table 1). 
Typical tectal gliomas were not present. More than half of the gliomas showed contrast 
enhancement on the initial MRI (13 versus 8; Table 1). Exophytic tumor growth was rare 
(n=5; Table 1). Representative MRIs are shown in Fig.1. 
 
Histology and molecular biology 
Histological diagnosis was mainly achieved by biopsy (n=15; Table 1). A minority of patients 
underwent a partial resection (n=4). Two pilocytic astrocytomas (WHO grade I) were 
macroscopically resected. In all 13 gadolinium-enhancing LG-and HG-BSGs the tumor 
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samples were derived from areas of contrast enhancement. Histological diagnosis revealed 
glioblastoma (WHO grade IV, n=6), anaplastic astrocytoma (WHO grade III, n=7) and diffuse 
astrocytoma (WHO grade II, n=6) (Table 2). There were no oligodendrogliomas or mixed 
oligoastrocytic gliomas.  
Molecular analysis was available in only seven cases (Table 2) mainly due to the limited 
tumor material and non-standardized institutional guidelines for diagnostic work-up. IDH 1/2 
wild-type status was determined in one LG- and three HG-BSGs. A germline p53 mutation 
was found in a GBM patient suffering from a Li-Fraumeni syndrome. In one LG-BSG the p53 
gene was determined as wild type. The MGMT promoter region was unmethylated in two 
HG-BSGs. Loss of heterozygosity of chromosome 1p and 19q was absent in one patient with 
an anaplastic astrocytoma.  
 
Therapy and outcome 
At the time of analysis (August 2013) nine patients are still alive and twelve have died from 
progressive disease. The median follow-up of patients being alive is 23.9 months. 
Neurological deterioration was observed in three patients after biopsy (patient 10,12) or 
gross total resection (patient 2) (Table1). In patient 2 permanent postoperative oculomotor 
symptoms persisted. In patient 10 and 12 pre-existing hemi-hypoesthesia and dysphagia 
initially worsened but partially recovered within months. Treatment and outcome after 
diagnosis are summarized in table 3. Radiotherapy was given to 15 patients, temozolomide 
chemotherapy was administered concomitantly in 9 patients. In 2 patients with high-grade 
tumors chemotherapy alone was prescribed postoperatively (temozolomide). Irradiation was 
rejected because of previous prophylactic CNS irradiation for a hematologic neoplasia 
(patient 10) or to avoid clinical deterioration due to radiation-induced edema (patient 13). 
Focal fractionated external beam irradiation was delivered to a median dose of 54 Gy in 
conventional fractionation (range 50.4-55.8 Gy). HGG were treated to a median dose of 57.6 
Gy, the doses varying widely from two patients being treated with a hypofractionated regimen 
with 39.75 Gy in 15 fractions, to patients treated in conventional fractionation (1.8 - 2 Gy) 
from 45 to 60 Gy.  Stereotactic radiosurgery was neither prescribed for initial nor for recurrent 
disease. No postoperative therapy was recommended for three patients with LG-BSGs, while 
in one of them, rapid tumor progression did not allow further antitumor therapy.  
Durable disease stabilization from 7.3 - 95.8 months was observed in five patients with LG-
BSGs. Three patients with HG-BSGs and one patient with a LG-BSG died of progressive 
disease during the initial treatment phase. Ten patients with HG-BSGs and two patients with 
LG-BSGs progressed. We excluded two patients with a pilocytic astrocytoma as a different 
disease entity in the outcome analysis (Fig. 2). Median PFS of LG-BSG was significantly 
better with 24.1 months compared to 5.8 months in HG-BSGs, respectively (log-rank, 
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p=0.009). Subsequent salvage therapy consisted of anti-VEGF treatment with bevacizumab 
(n=4), and chemotherapy with temozolomide (n=4) or lomustine (n=2). One patient each 
underwent salvage radiotherapy or radiochemotherapy at progression after failure of initial 
chemotherapy. Third-line therapy in HG-BSGs consisted of bevacizumab in three patients. 
None of the patients underwent a second surgery or any kind of re-irradiation for progressive 
disease. Median OS in patients suffering from LG-BSGs (n=6) and HG-BSGs (n=13) was 
statistically different with 30.5 and 11.5 months, respectively (log-rank, p=0.028) (Table 3, 
Fig. 2b). Log-rank test of mPFS and mOS of contrast enhancing versus non-contrast 
enhancing brainstem gliomas were statistically not significant. 
 
Discussion 
The current study represents the largest contemporary clinical investigations of histologically 
verified adult brainstem gliomas. Most recent studies on BSG were retrospective case series 
with small and heterogeneous cohorts. All but one series [9] mixed adults and children [2; 8; 
16-19], various proportions of histologically non-verified brainstem lesions ranging from 10 to 
72% [2-4; 8; 10; 16-19] or a combination of both [2; 8; 16-19].  The only prospective study 
investigated fractionated stereotactic radiotherapy in both pediatric and adult patients, and 
included many patients without histological diagnosis [18]. The impact of non-malignant or 
even non-glial lesions (i.e. metastasis, inflammation) [6; 20], distinct molecular pathology of 
histone H3 alterations in pediatric BSG [21] and different prognosis in children and adults 
remains elusive [2; 4]. Histological verification of suspected brainstem tumors is key for 
appropriate subsequent therapy as the concordance of MRI imaging and histological 
diagnosis is low. The presumed glioma diagnosis in a cohort of 30 patients could 
histologically be confirmed in only 63%, the others being lymphomas, metastasis or 
inflammatory lesions [6]. This finding underscores the importance of exact histological 
diagnosis before making clinical treatment decisions [20; 22]. Most series do not distinguish 
between low- and high-grade gliomas, although the prognosis and outcome is greatly 
influenced by tumor grade. In one study survival of diffuse intrinsic LG-BSG was 7.3 years 
compared with only 12 months in patients with high-grade BSGs [3].  
In our cohort only histologically confirmed diffuse tumors of adults were included. Median age 
of LG-BSG was lower (34 versus 48 years) and outcome measured in terms of mPFS and 
mOS was as expected better than in high grade tumors (Fig 1 a, b). Interestingly, contrast 
enhancement on MRI was also commonly detected in LG-BSGs. This has already been 
reported in a correlation study of MRI findings and histologically verified brainstem lesions 
and is also observed in pediatric LG-BSG [23]. Although contrast enhancement in low-grade 
gliomas of supratentorial localization are frequently associated with an oligodendroglial 
histology, oligodendrogliomas are rarely the cause for brainstem gliomas [24]. Our cohort did 
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also not contain any brainstem oligodendroglioma [2-4; 8; 9]. Histological grading of BSGs 
might be limited due to small and non-representative specimens of the tumor for histological 
diagnosis. This especially accounts for biopsies. However, in our cohort all patients with 
contrast enhancement on the preoperative MRI tumor tissue were derived from a gadolinium 
enhancing area which contributes to the quality of histological diagnosis.   
By its location, brainstem glioma poses particular challenges to treatment with radiotherapy. 
Large parts of the planning process for non-brainstem gliomas are devoted to sparing the 
brainstem of higher doses. This is obviously not possible in BSG. In the 1990s, dose 
constraints were often based on the Emami review, which at the time of publication in 1991, 
specified a 5-year, 5%-rate of ‘‘necrosis/infarct’’ would result from 50, 53, and 60 Gy 
delivered to the whole, two thirds, and one third of the brainstem, respectively [25]. Several 
trials have subsequently defined the dose-maximum constraints to the brainstem to be in the 
range of 50 to 55 Gy. Newer analyses estimate that the entire brainstem may be treated to 
54 Gy using conventional fractionation with limited risk of severe or permanent neurological 
deficits [26]. Smaller volumes of the brainstem (1–10 cc) may be irradiated to maximum 
doses of 59 Gy for dose fractions </= 2 Gy. The risk appears to increase markedly at doses 
>64 Gy. However, there is insufficient information to determine whether there is a further 
volume effect [27]. The large variations of applied radiotherapy doses in our study reflect the 
lack of a well-established standard of care. In our series we did not observe any radiotherapy 
associated brainstem injury, and no increase in toxicity was seen in patients who received 
concomitant and adjuvant temozolomide. The current literature so far reported only common 
hematological toxicities in adults receiving concomitant and adjuvant temozolomide for BSG 
[8; 9]. This is a clinical relevant finding in the absence of a prospective trial as chemotherapy 
after radiation has been shown to increase the risk of CNS-radionecrosis by approximately 
fivefold [28]. Although feasibility has been established [29-31] and stereotactic radiotherapy 
is readily available in Switzerland, none of the patients in our series was treated with 
radiosurgery. 
Various chemotherapeutics were used for salvage treatment including anti-VEGF treatment 
with bevacizumab. Still, efficacy of salvage chemotherapy was low with a median PFS of 2.6 
months (range, 1-50 months) and a PFS after six months of 18%. 
Our study has several limitations due to its retrospective design and the small cohort size. 
Treatment recommendations for HG- and LG-BSG cannot be deduced. In the absence of 
standardization, the definition of clinical and radiological progression relied on the discretion 
of the physician. Furthermore, genetically data were scarce and do not provide any new 
clues for the molecular characterization of adult BSGs. However, it is the largest study 
reported so far distinctively investigating outcome of histologically verified adult BSG.  
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In conclusion, histologically verification of brainstem gliomas is feasible, has an impact on the 
therapeutic strategy and avoids false diagnoses which require different treatment 
approaches. The benefit of a correct diagnosis has to be weight against the risk of brainstem 
surgery on an individual decision basis. Given the relatively good prognosis in LG-BSG 
achieved with no postoperative treatment or radiotherapy alone potential harmful therapies 
can be avoided by histologically verified tumor grading. In contrast, given the worse 
prognosis of HG-BSGs combined radiochemotherapy with temozolomide should be an option 
due to low additional toxicity albeit the lacking evidence of efficacy. Future approaches in 
HG-BSGs may investigate benefits from adding bevacizumab to radiochemotherapy as it 
may contribute to anti-tumor effects and prevent side effects from radiotherapy in higher 
doses in this eloquent brain region. 
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Table 1 
Individual patient and imaging characteristics (ID 1-8, low-grade gliomas; ID 9-21, high-grade 
gliomas) 
 
Table 2 
Results of histological and molecular investigations 
 
Table 3 
Therapy and outcome 
 
Fig 1 
Transversal MRI scans of a medullary low-grade brainstem glioma (a, T1-weighted, T1-
weighted + Gadolinium; T2-weighted) and a ponto-medullary glioblastoma of the brainstem 
(b, T1-weighted, T1-weighted + Gadolinium; T2-weighted). The glioma is indicated with a 
white arrow 
 
Fig 2  
Kaplan-Meier estimates of PFS (a) and overall survival (b) for low-grade (LG-BSG, blue line)) 
and high-grade brainstem gliomas (HG-BSG, green line) (n=19). Pilocytic astrocytomas 
(n=2) were excluded from outcome analysis. 
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 Table 1:  
 
ID age [years] 
main 
location 
initial 
symptoms 
exophytic 
growth 
type of 
surgery 
location of 
surgery  CE 
specimen 
of  
CE area 
postoperative 
deterioration 
1 29 pons headache, dizziness + 
gross total 
resection pons + + no 
2 39 midbrain, pons 
sensorimotor 
hemisyndrome - 
gross total 
resection 
pedunculus 
cerebri + + yes 
3 48 midbrain, pons 
hiccup, 
dizziness - 
partial 
resection 
floor of the 
4th ventricle - n/a no 
4 57 medulla diplopia, dizziness - biopsy 
nuclei  
olivaris + + no 
5 28 pons diplopia headache - biopsy pons - n/a no 
6 71 midbrain, pons,  medulla 
ataxia, 
diplopia - biopsy pons - n/a no 
7 25 pons headache - biopsy brachium 
pontis  
+ + no 
8 24 midbrain diplopia - biopsy thalamus - n/a no 
9 52 midbrain,  pons 
ataxia, 
nausea - biopsy pons + + no 
10 41 pons Hemi-hypoesthesia, pain - biopsy pons - n/a yes 
11 48 pons, medulla  
hemisyndrome, 
tremor + biopsy pons - n/a no 
12 40 midbrain 
abducent nerve palsy, 
dysphagia + biopsy pons + + yes 
 13 27 pons trigeminal symptoms, double vision, dysphagia - biopsy pons - n/a no 
14 48 pons hydrocephalus occlusus - biopsy obex + + no 
15 23 midbrain ataxia,  
fatigue 
- biopsy cerebellar 
hemisphere 
- n/a no 
16 33 pons ataxia, double vision - biopsy thalamus + + no 
17 55 medulla trigeminal palsy, ataxia - biopsy 
cerebellar 
hemisphere + + no 
18 20 pons ataxia, dysarthria - 
partial 
resection 
cerebellar 
hemisphere + + no 
19 81 midbrain, pons 
trigeminal palsy, 
ataxia + 
partial 
resection pons + + no 
20 53 midbrain hemiparesis - biopsy pons + + no 
21 67 midbrain,  pons 
hemiparesis, 
headaches + 
partial 
resection pons + + no 
 
Abbreviations: ID, identification; n/a, not applicable; CE, contrast enhancement 
 Table 2:  
 
ID WHO grade histology 
MGMT 
promoter 
methylation 
IDH 1/2 
mutation 
p53 
mutation 
1p/19q 
co-deletion 
1 I PA n/a n/a n/a n/a 
2 I PA n/a n/a n/a n/a 
3 II A n/a n/a n/a n/a 
4 II A n/a n/a n/a n/a 
5 II A n/a wt/wt wt n/a 
6 II A n/a n/a n/a n/a 
7 II A n/a n/a n/a n/a 
8 II A n/a n/a n/a n/a 
9 III AA n/a n/a n/a n/a 
10 III AA n/a wt/wt n/a n/a 
11 III AA n/a n/a n/a intact 
12 III AA negative n/a n/a n/a 
 13 III AA n/a wt/wt mutant n/a 
14 III AA n/a n/a n/a n/a 
15 III AA n/a n/a n/a n/a 
16 IV GBM n/a n/a n/a n/a 
17 IV GBM n/a n/a n/a n/a 
18 IV GBM n/a n/a mutant n/a 
19 IV GBM n/a n/a n/a n/a 
20 IV GBM n/a n/a n/a n/a 
21 IV GBM negative wt/wt n/a n/a 
 
Abbreviations: ID, identification; n/a, not applicable; wt, wild type, PA, pilocytic astrocytoma; A, diffuse astrocytoma; AA, anaplastic 
astrocytoma, GBM, glioblastoma multiforme 
Table 3: Therapy and outcome 
 
 
 
 LG-BSG 
n=8 
HG-BSG 
n=13 
postoperative therapy 
no treatment 
radiotherapy 
radiochemotherapy (with temozolomide) 
chemotherapy 
 
3 
3 
2 
0 
 
1 
3 
7 
2 
median PFS after postoperative treatment1    
months  
(range) 
 
24.1 
(1.5-95.8) 
 
5.8  
(2.4-13.3) 
median OS1  
months  
(range) 
 
30.5  
(4.4-95.8) 
 
11.5  
(3.6-54.7) 
 
1 two patients with pilocytic astrocytomas were excluded from the analysis 
 
